COMMUNIQUÉS West-GlobeNewswire

Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
26/06/2026
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the [...]
Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update
26/06/2026
Revenue increased by 107% year-over-year to $7.7 million in the full fiscal year 2026; increased revenue by 66% YoY in the fiscal fourth quarter 2026 The Company is transitioning its year-end from March 31 st to [...]
Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology
26/06/2026
The allowed Patent strengthens protection in one of the world's largest pharmaceutical markets and further supports Namodenoson's positioning in obesity and metabolic diseases Ramat Gan, Israel, June 26, 2026 (GLOBE [...]
Tilray Medical Expands Medical Cannabis Access for Veterans Through Lyphe Clinic at Aldershot’s Armed Forces Weekend
26/06/2026
Lyphe Clinic, Tilray’s trusted medical cannabis clinic, will engage veterans, service members and families through its Lyphe for Veterans access programme. The Aldershot activation highlights Tilray Medical’s commitment [...]
Fortrea Names Jason Knoblauch as Chief Financial Officer
26/06/2026
Jason Knoblauch will succeed Jill McConnell as chief financial officer of Fortrea DURHAM, N.C., June 26, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization ( [...]
Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy
26/06/2026
BALTIMORE, June 26, 2026 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc ., a clinical-stage biotechnology company developing treatments for rare diseases and aging-associated diseases, today announced that it has [...]
Transcom Leading Voices Connects CX Executives Through Peer Learning
26/06/2026
Transcom opens Leading Voices, a platform of real-world advice from leaders working through AI adoption in customer experience. It pairs peer perspectives and learning tools with Transcom's own proven CX results, from [...]
Idorsia confirms successful closing of Pharmakon loan agreement and full repayment of New Money Facility
26/06/2026
Allschwil, Switzerland – June 26, 2026 Idorsia Ltd (SIX: IDIA), a commercial-stage biopharmaceutical company with a portfolio of first- or best-in-class assets, today confirmed the successful closing of its previously [...]
Résultats de l’Assemblée Générale Mixte de Cellectis du 25 juin 2026
25/06/2026
NEW YORK, 25 juin 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome pour développer des [...]
MEDIROM MOTHER Labs Expands Deployment of "REMONY®" Remote Health Monitoring System in JGSDF 8th Division
25/06/2026
Additional Orders Triple Implementation Scale; "MOTHER Bracelet®" Enables Continuous Safety Monitoring During Extended Training TOKYO, June 25, 2026 (GLOBE NEWSWIRE) -- MEDIROM MOTHER Labs Inc. (Headquarters: Minato-ku [...]
Canadian Red Cross launches appeal to support people impacted by the earthquakes in Venezuela
25/06/2026
OTTAWA, Ontario, June 25, 2026 (GLOBE NEWSWIRE) -- The Canadian Red Cross is working to support those impacted by the earthquakes in Venezuela and has launched the 2026 Venezuela Earthquakes Appeal . The Red Cross is [...]
La Croix-Rouge canadienne recueille des dons pour apporter de l’aide dans la foulée des séismes au Vénézuéla
25/06/2026
OTTAWA, Ontario, 25 juin 2026 (GLOBE NEWSWIRE) -- La Croix-Rouge canadienne a mis sur pied le Fonds de secours : Séismes au Vénézuéla afin de prêter assistance aux personnes éprouvées par la récente catastrophe. La [...]
Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026
25/06/2026
NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell [...]
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
25/06/2026
LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced [...]
Eikon Therapeutics to Join the Russell 3000® Index
25/06/2026
Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment community MILLBRAE, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“ [...]
DLH Contract Award Opens New Growth Channels with U.S Navy
25/06/2026
ATLANTA, June 25, 2026 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of digital transformation and cybersecurity, systems engineering and integration, and science [...]
Keros Therapeutics Appoints Anne Prener to its Board of Directors
25/06/2026
LEXINGTON, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute
25/06/2026
WILMINGTON, Del., June 25, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx” or the “Company”) today issued the following statement in response to recent public claims made by Kadima [...]
Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026
25/06/2026
COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its clinical development programs for the treatment of children with achondroplasia [...]

Pages